Identification of an 11-lncRNA signature with high performance for predicting the prognosis of hepatocellular carcinoma using bioinformatics analysis. Issue 5 (5th February 2021)

• Record Type: Journal Article
• Authors: Wang, Anmei; Lei, Junhua
• Other Names: Sun. YX section editor.
• Is Part Of: Medicine. Volume 100:Issue 5(2021)
• Publication Date: 2021-02-05
• Subjects: bioinformatics -- competitive endogenous RNA -- enrichment analysis -- hepatocellular carcinoma -- risk score; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000023749
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Hepatocellular carcinoma (HCC) is a common primary liver cancer with a high incidence and mortality. This study was conducted to identify a long non-coding RNA (lncRNA) signature that may serve as a predictor for HCC prognosis. RNA-seq data were extracted from The Cancer Genome Atlas database. Differentially expressed genes, lncRNAs, and miRNAs were identified in HCC (n = 374) and control samples (n = 50) and used to screen prognosis-associated lncRNA signatures. The association of the lncRNA signature with HCC prognosis was analyzed and a competitive endogenous RNA regulatory network involving the lncRNA signature was constructed. A total of 199 mRNAs, 1092 lncRNAs, and 251 miRNAs were differentially expressed between HCC and control samples. Among these lncRNAs, 11 prognosis-associated lncRNAs were used to construct a lncRNA signature. Cox regression analysis showed that patients with higher risk scores of the lncRNA signature were at risk of poor prognosis. Four lncRNAs (including LINC01517, DDX11-AS1, LINC01136, and RP11-20J15.2 ) and 7 miRNAs (including miR-195, miR-199b, miR-326, miR-424, and let-7c ) in the ceRNA network interacted with the upregulated gene E2F2, which was associated with the overall prognosis of patients with HCC. The 11-lncRNA signature might be useful for predicting the prognosis of patients with HCC.